What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Chinook Therapeutics (NASDAQ:KDNY) received 1 bullish, 3 somewhat bullish, and 2 indifferent analyst ratings. The average 12-month price target is $36.17, a 7.26% decrease from the previous average of $39.00.
June 12, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Chinook Therapeutics received mixed analyst ratings in the last quarter, with an average 12-month price target of $36.17, down 7.26% from the previous average.
The mixed analyst ratings for Chinook Therapeutics indicate uncertainty in the stock's short-term performance. With 1 bullish, 3 somewhat bullish, and 2 indifferent ratings, the stock's direction is unclear. The average 12-month price target has decreased by 7.26%, which may impact investor sentiment but does not provide a clear indication of the stock's short-term price direction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100